VIVUS Inc., Currax Pharmaceuticals LLC. and Mylan N.V. are Dominating in the U.S. Anorexiants Market in 2019

The U.S. Anorexiants Market is expected to grow with the CAGR of 3.5% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below:

Access full Report @

The U.S. anorexiants market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in the U.S. anorexiants market are introducing strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, award and recognition into the anorexiants market. This helped companies to maximize the sales with enhanced product portfolio. For instance, in October 2019, VIVUS Inc. received marketing authorization for Qsymia from European regulatory agencies in Denmark, Finland, Norway, Sweden and Poland. This authorization helped the company to enhance its product sales in different regions around the world which has led to generate more revenue.

VIVUS Inc. is the dominating player in the U.S. anorexiants market. The other key players existing in the anorexiants market are KVK Tech, Inc., Currax Pharmaceuticals LLC., Recordati Rare Diseases (a subsidiary of RECORDATI S.p.A.), Aurobindo Pharma USA (a subsidiary of Aurobindo Pharma), Sun Pharmaceutical Industries Ltd., Pfizer Inc., Teva Pharmaceutical USA Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), sanofi-aventis U.S. LLC (a subsidiary of Sanofi), Hikma Pharmaceuticals PLC, Lannett, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Dr. Reddy’s Laboratories Ltd., Sandoz AG (a business division of Novartis AG), Mylan N.V., Bausch Health Companies Inc., Cipla Inc., Par Pharmaceutical (a subsidiary of Endo International plc), and Amphastar Pharmaceuticals, Inc. among others.

U.S. Anorexiants MarketVIVUS Inc.:

VIVUS Inc. is headquartered in California, U.S. and was incorporated in 1991. The company is engaged in clinical development and commercialization of new medicines in order to meet the various therapeutic needs of patients having serious medical conditions and life- limiting diseases. The company has two products named as pancreaze and qsymia in which qsymia is the market focused product.

For instance,

  • In June 2019, VIVUS Inc. launched an online platform for sale of Qsymia, an anorexiants used for obesity treatment. This platform launch helped the company to boost the product sales in different regions of the world.

The company has wide presence across North America, Europe, and Asia. The company also has various subsidiary companies such as Willow Biopharma Inc. (Canada), VIVUS BV Ltd (Netherlands), VIVUS International Ltd. (Ireland), VIVUS UK Ltd (U.K.), VIVUS Ireland Ltd (Ireland) among others.

Currax Pharmaceuticals LLC.:

Currax Pharmaceuticals LLC. is headquartered in New Jersey, U.S. The company is focused on creating challenge for it to think differently and to inspire each other so as to enhance the lives of patients by providing them access to life changing medications. The company has two product categories which are branded products, and generic products in which branded products is the market focused category.

For instance,

  • In September 2019, Currax Pharmaceuticals LLC. acquired Nalpropion Pharmaceuticals, a company engaged in manufacturing of contrave, an anorexiants drug indicated for obesity treatment in patients having BMI of 27 to 30 or more than this. This acquisition helped the company to boost its product portfolio by involvement of one more product, which enhanced the company’s sale.

The company has presence across North America. The company has two subsidiaries which are Nalpropion, Inc. (U.S.) and Pernix Therapeutics Holdings, Inc. (U.S.).

Mylan N.V.:

Mylan N.V. is headquartered in Pennsylvania, U.S. The company focuses on manufacturing of high quality medicines involving generics, branded generics, over the counter and biosimilar drugs as per the new healthcare standards. The company has various product categories which are biosimilars, generics, brand, over the counter and API among which generics is the market focused category.

For instance,

  • In June 2018, Mylan N.V. received Power of Partnership Award by Americares in partnership with Healthcare Distribution Alliance (HDA). The company has been awarded in recognition of its outstanding product portfolio accessible to a huge American population. The company is engaged in manufacturing of generic anorexiants drugs used for obesity treatment, hence, this award and recognition helped the company to get recognized for its anti-obesity product portfolio.

The company has presence across North America, Europe, South America, Asia-Pacific and Middle East and Africa. The company has various subsidiaries which are Agila Australasia Pty Ltd (Australia), Alphapharm Pty. Ltd. (Australia), Meda Pharmaceuticals Pty Ltd (Australia), Mylan Australia Holding Pty Ltd (Australia), Mylan Health Pty. Ltd. (Australia), Arcana Arzneimittel GmbH (Austria) among others.